Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 2 , Pages 193-208 , April 2009

Management of the child with congenital adrenal hyperplasia

  • Peter C. Hindmarsh, BSc, MD, FRCP, FRCPCH (Professor of Paediatric Endocrinology)

      Affiliations

    • Corresponding Author InformationTel.: +44 207 905 2840; Fax: +44 207 905 2838.

References 

  1. New MI, Wilson RC. Steroid disorders in children: congenital adrenal hyperplasia and apparent mineralocorticoid excess. Proceedings of the National Academy of Sciences of the United States of America. 1999;96:12790–12797
  2. White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocrine Reviews. 2000;21:245–291
  3. Van Wyk JJ, Gunther DF, Ritzen EM, et al. The use of adrenalectomy as a treatment for congenital adrenal hyperplasia. The Journal of Clinical Endocrinology and Metabolism. 1996;81:3180–3190
  4. Butler DA, Lawlor MT. It takes a village: helping families live with diabetes. Diabetes Spectrum. 2004;17:26–31
  5. Schneider CE. The practice of autonomy. New York: Oxford University Press; 1998;
  6. Kelley DL. How to use control charts for healthcare. Milwaukee: ASQ Quality Press; 1999;
  7. Priestland A, Hanig R. Developing first level leaders. Harvard Business Review. 2005;83:112–120
  8. Lee PA, Houk CP, Ahmed SF, Hughes IA, International Consensus Conference on Intersex organized by the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology . Consensus statement on management of intersex disorders. International Consensus Conference on Intersex. Pediatrics. 2006;118:488–500
  9. Krone N, Dhir V, Ivison HE, et al. Congenital adrenal hyperplasia and P450 oxidoreductase deficiency. Clinical Endocrinology. 2007;66:162–172
  10. Swerdlow AJ, Higgins C, Brook CGD, et al. Mortality in patients with congenital adrenal hyperplasia: A cohort study. The Journal of Pediatrics. 1998;133:516–520
  11. Mullis PE, Hindmarsh PC, Brook CGD. Sodium chloride supplement at diagnosis and during infancy in children with salt-losing 21-hydroxylase deficiency. European Journal of Pediatrics. 1990;150:22–25
  12. The fourth report on the diagnosis, evaluation and treatment of high blood pressure in children and adolescents. US Department of Heath and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute; 2005;
  13. Minto CL, Liao LM, Woodhouse CR, et al. The effect of clitoral surgery on sexual outcome in individuals who have intersex conditions with ambiguous genitalia: a cross-sectional study. Lancet. 2003;12:1252–1257
  14. Stewart PM. The adrenal cortex. In:  Kronenberg HM,  Melmed S,  Polonsky K, et al. editor. Williams textbook of endocrinology. 11th edn.. Philadelphia: Saunders Elsevier; 2008;p. 459
  15. Miller WL. The adrenal cortex and its disorders. In:  Brook CGD,  Hindmarsh PC editor. Clinical paediatric endocrinology. 4th edn.. Oxford: Blackwell Science; 2001;p. 350
  16. Charmandari E, Hindmarsh PC, Johnston A, et al. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: alterations in cortisol pharmacokinetics at puberty. The Journal of Clinical Endocrinology and Metabolism. 2001;86:2701–2708
  17. Moore JS, Monson JP, Kaltsas G, et al. Modulation of 11β-hydroxysteroid dehydrogenase isozymes by growth hormone and insulin-like growth factor: in vivo and in vitro studies. The Journal of Clinical Endocrinology and Metabolism. 1999;84:4172–4177
  18. L'Allemand D, Penhoat A, Lebrethon MC, et al. Insulin-like growth factors enhance steroidogenic enzyme and corticotropin receptor messenger ribonucleic acid levels and corticotropin steroidogenic responsiveness in cultured human adrenocortical cells. The Journal of Clinical Endocrinology and Metabolism. 1996;81:3892–3897
  19. Moghetti P, Castello R, Negri C, et al. Insulin infusion amplifies 17 alpha-hydroxycorticosteroid intermediates response to adrenocorticotropin in hyperandrogenic women: apparent relative impairment of 17,20-lyase activity. The Journal of Clinical Endocrinology and Metabolism. 1996;81:881–886
  20. Zisper RD, Speckart PF, Zia PK, et al. The effect of ACTH and cortisol on aldosterone and cortisol clearance and distribution in plasma and whole blood. The Journal of Clinical Endocrinology and Metabolism. 1976;43:1101–1109
  21. Singh A, Hamilton-Fairley D, Koistinen R, et al. Effect of insulin-like growth factor-type I (IGF-I) and insulin on the secretion of sex hormone binding globulin and IGF-I binding protein (IBP-I) by human hepatoma cells. The Journal of Endocrinology. 1990;124:R1–R3
  22. Smith FM, Latchford GJ, Hall RM, et al. Do chronic medical conditions increase the risk of eating disorder? A cross-sectional investigation of eating pathology in adolescent females with scoliosis and diabetes. The Journal of Adolescent Health. 2008;42:58–63
  23. Rivkees SA, Danon M, Herrin J. Prednisone dose limitation of growth hormone treatment of steroid-induced growth failure. The Journal of Pediatrics. 1994;125:322–325
  24. Van der Kamp HJ, Otten BJ, Buitenweg N, et al. Longitudinal analysis of growth and puberty in 21-hydroxylase deficiency patients. Archives of Disease in Childhood. 2002;87:139–144
  25. Bonfig W, Bechtold S, Schmidt H, et al. Reduced final height outcome in congenital adrenal hyperplasia under prednisone treatment: deceleration of growth velocity during puberty. The Journal of Clinical Endocrinology and Metabolism. 2007;92:1635–1639
  26. Styne DM, Richards GE, Bell JJ, et al. Growth patterns in congenital adrenal hyperplasia. Correlation of glucocorticoid therapy with stature. In:  Lee PA,  Plotnich LP,  Kowarski AA, et al. editor. Congenital adrenal hyperplasia. Baltimore: University Park Press; 1997;p. 247–261
  27. Migeon CJ, Donohue PA. Congenital adrenal hyperplasia caused by 21-hydroxylase deficiency. Its molecular basis and its remaining therapeutic problems. Endocrinology and Metabolism Clinics of North America. 1991;20:277–296
  28. DiMartino-Nardi J, Stoner E, O'Connell A, et al. The effect of treatment on final height in classical congenital adrenal hyperplasia (CAH). Acta Endocrinologica Supplementum. 1986;279:305–313
  29. Jaaskelainen J, Voutilainen R. Growth of patients with 21-hydroxylase deficiency: an analysis of the factors influencing adult height. Pediatric Research. 1997;41:30–33
  30. Manoli I, Kanaka-Gantenbein Ch, Voutetakis A, et al. Early growth, pubertal development, body mass index and final height of patients with congenital adrenal hyperplasia: factors influencing the outcome. Clinical Endocrinology. 2002;57:669–676
  31. Lin-Su K, Vogiatzi MG, Marshall I, et al. Treatment with growth hormone and luteinizing hormone releasing hormone analog improves final adult height in children with congenital adrenal hyperplasia. The Journal of Clinical Endocrinology and Metabolism. 2005;90:3318–3325
  32. Cornean RE, Hindmarsh PC, Brook CGD. Obesity in 21-hydroxylase deficient patients. Archives of Disease in Childhood. 1998;78:261–263
  33. Völkl TM, Simm D, Beier C, et al. Obesity among children and adolescents with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Pediatrics. 2006;117:e98–105
  34. Hague WM, Adams J, Rodda C, et al. The prevalence of polycystic ovaries in patients with congenital adrenal hyperplasia and their close relatives. Clinical Endocrinology. 1990;33:501–510
  35. Stikkelbroeck NM, Hermus AR, Schouten D, et al. Prevalence of ovarian adrenal rest tumours and polycystic ovaries in females with congenital adrenal hyperplasia: results of ultrasonography and MR imaging. European Radiology. 2004;14:1802–1806
  36. Stikkelbroeck NM, Suliman HM, Otten BJ, et al. Testicular adrenal rest tumours in postpubertal males with congenital adrenal hyperplasia: sonographic and MR features. European Radiology. 2003;13:1597–1603
  37. Claahsen-van der Grinten HL, Sweep FC, Blickman JG, et al. Prevalence of testicular adrenal rest tumours in male children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. European Journal of Endocrinology. 2007;157:339–344
  38. Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinology and Metabolism Clinics of North America. 2004;33:283–303
  39. Kahn R. Metabolic syndrome–what is the clinical usefulness?. Lancet. 2008;371:1892–1893
  40. Sattar N, McConnachie A, Shaper AG, et al. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet. 2008;371:1927–1935
  41. Charmandari E, Weise M, Bornstein SR, et al. Children with classic congenital adrenal hyperplasia have elevated serum leptin concentrations and insulin resistance: potential clinical implications. The Journal of Clinical Endocrinology and Metabolism. 2002;87:2114–2120
  42. Roche EF, Charmandari E, Dattani MT, et al. Blood pressure in children and adolescents with congenital adrenal hyperplasia (21-hydroxylase deficiency): a preliminary report. Clinical Endocrinology. 2003;58:589–596
  43. Merke DP, Chrousos GP, Eisenhofer G, et al. Adrenomedullary dysplasia and hypofunction in patients with classic 21-hydroxylase deficiency. The New England Journal of Medicine. 2000;343:1362–1368
  44. Doyle LW, Ford GW, Davis NM, et al. Antenatal corticosteroid therapy and blood pressure at 14 years in preterm children. Clinical Science. 2000;98:127–128
  45. Mangos GJ, Turner SW, Fraser TB, et al. The role of corticosterone in corticotrophin (ACTH)-induced hypertension in the rat. Journal of Hypertension. 2000;18:1849–1855
  46. Whitworth JA, Schyvens CG, Zhang Y, et al. Glucocorticoid-induced hypertension: from mouse to man. Clinical and Experimental Pharmacology and Physiology. 2001;28:993–996
  47. Tunstall-Pedoe H. Myth and paradox of coronary risk and the menopause. Lancet. 1998;351:1425–1427
  48. Gussinyé M, Carrascosa A, Potau N, et al. Bone mineral density in prepubertal and in adolescent and young adult patients with the salt-wasting form of congenital adrenal hyperplasia. Pediatrics. 1997;100:671–674
  49. Paganini C, Radetti G, Livieri C, et al. Height, bone mineral density and bone markers in congenital adrenal hyperplasia. Hormone Research. 2000;54:164–168
  50. Department of Health . Transition: getting it right for young people: improving the transition of young people with long term conditions from children's to adult health services. Available from: http://www.dh.gov.uk/PublicationsAndStatistics/Publications/PublicationsPolicyAndGuidance/PublicationsPolicyAndGuidanceArticle/2006;
  51. Datta J. Moving up with diabetes: the transition from paediatric to adult care. National Children's Bureau. 2003;
  52. Dovey-Pearce G, Hurrell R, Doherty Y. Young adults' (16–25 years) suggestions for providing developmentally appropriate diabetes services: a qualitative study. Health and Social Care in the Community. 2005;13:409–419

PII: S1521-690X(08)00122-X

doi: 10.1016/j.beem.2008.10.010

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 2 , Pages 193-208 , April 2009

Article Tools

* Image Usage & Resolution